Abstract:Objective: To develop a method for determining the concentration of axitinib in beagle dog plasma and utilize this method to investigate the pharmacokinetics of orally administered axitinib in beagle dogs. Methods: Plasma samples were processed using acetonitrile precipitation and analyzed by UPLC-MS/MS with sunitinib as an internal standard (IS). Chromatographic separation was achieved on a Waters Acquisition UPLC BEH C18 column (50 mm × 2.1 mm, 1.7 μm) with a gradient elution of acetonitrile and 0.1 % formic acid. Mass spectrometry uses an electrospray ion source for positive ion detection in a multiple reaction monitoring mode. The monitored ion transitions for axitinib and sunitinib were m/z 387 → 355.96 and m/z 399.3 → 282.96, respectively. Six beagle dogs were administered 0.33 mg/kg of axitinib orally, and venous blood samples were collected at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 h post-dose for pharmacokinetic analysis. Results: The assay demonstrated a linear range of 0.5-100 ng/mL (r2 = 0.9992), and the lower limit of quantification was up to 0.5 ng/mL. Precision, as assessed by relative standard deviation (RSD), was within 8.64 % for both intraday and interday variability. The relative error (RE) for precision from -2.77 %-1.20 %. The recovery rate of the analytes exceeded 85.28 % and the matrix effect was approximately 100 %. Plasma samples maintained stability under various conditions, including room temperature storage for 12 h, processed on an automatic sampler at 4 °C for 6 h, three freeze-thaw cycles, and long-term storage at -80 °C for 60 days. Pharmacokinetic parameters were determined using DAS 2.0 software, revealing a half-life (T1/2) of 6.05 h and an area under the curve (AUC (0 → ∞)) of 97.13 ng h/mL for axitinib. Conclusions: The UPLC-MS/MS method developed in this study offers high specificity, rapid analysis, high recovery, excellent linearity, and minimal plasma volume requirements, making it well-suited for pharmacokinetic and drug interaction studies in beagles dogs.

Toxicokinetics of CXY-001 Following Single and Repeated Administration to Beagle Dogs

Research on the Long-Term Toxicological Effects of Suxiaokangyun Capsules in Beagle Dogs

Assessment of Thirteen-Week Subchronic Oral Toxicity of Cyadox in Beagle Dogs.

Pharmacokinetics of a New Derivative of Ginkgolide B and Its Absolute Bioavailability in Beagle Dogs

The 14-Day Repeated-Dose Toxicity Study of a Fixed-Dose Combination, QXOH/levobupivacaine, Via Subcutaneous Injection in Beagle Dogs

Study on Pharmacokinetics-Pharmacodynamics of Xinning Extended Action Tablet on Dogs

Pharmacokinetics and Metabolism of Cyadox and Its Main Metabolites in Beagle Dogs Following Oral, Intramuscular, and Intravenous Administration

Toxicokinetics of Naringin and Its Metabolite Naringenin after 180-Day Repeated Oral Administration in Beagle Dogs Assayed by a Rapid Resolution Liquid Chromatography/tandem Mass Spectrometric Method

Pharmacokinetics of Clematichinenoside AR and Its Absolute Bioavailability in Beagle Dogs

Pharmacokinetic Study of Single and Multiple Oral Administration of Glutamine in Healthy Beagles.

Beagle Dog 90-Day Oral Toxicity Study of a Novel Coccidiostat – Ethanamizuril

Pharmacokinetics of Docetaxel Liposomes Injection in Beagle Dogs by Liquid Chromatography-Mass Spectrometry

Toxicity Study of 28-Day Subcutaneous Injection of Arctigenin in Beagle Dogs

[Dose-dependent pharmacokinetic study of genistein in Beagle dogs].

Determination and Pharmacokinetics of MN9202 in Beagle Dogs

Pharmacokinetic study of two docetaxel preparations in Beagle dogs by a LC-MS/MS method (1064.5)

Pharmacokinetics and Relative Bioavailability of Sustained-Release Alfzosin Hydrochloride Capsules in Healthy Beagle Dogs

A Pharmacokinetic Study on Carteolol Hydrochloride Matrix Sustained-release Pellets in Beagle Dogs

Subchronic Toxicity and Toxicokinetics of MCC-555, a Novel Thiazolidinedione, after 270-Day Repeated Oral Administration in Dogs

UPLC-MS/MS analysis of axitinib and pharmacokinetic application in beagle dogs